Biohaven Gross Profit 2016-2022 | BHVN

Biohaven gross profit from 2016 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Biohaven Annual Gross Profit
(Millions of US $)
2021 $371
2020 $46
2019 $
2018 $
2017 $
2016 $
2015 $
Biohaven Quarterly Gross Profit
(Millions of US $)
2022-09-30
2022-06-30 $179
2022-03-31 $293
2021-12-31 $264
2021-09-30
2021-06-30 $76
2021-03-31 $31
2020-12-31 $25
2020-09-30 $13
2020-06-30 $7
2020-03-31 $1
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.982B $0.463B
Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $168.264B 10.27
GSK (GSK) United Kingdom $68.657B 8.61
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.145B 19.02
Ginkgo Bioworks Holdings (DNA) United States $3.570B 0.00
Myovant Sciences (MYOV) United Kingdom $2.594B 0.00
Arcus Biosciences (RCUS) United States $2.073B 31.12
Emergent Biosolutions (EBS) United States $0.579B 4.55
Zymeworks (ZYME) Canada $0.493B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.261B 0.00
Enzo Biochem (ENZ) United States $0.094B 0.00
SQZ Biotechnologies (SQZ) United States $0.078B 0.00
Gelesis Holdings (GLS) United States $0.028B 0.00
Ambrx Biopharma (AMAM) United States $0.019B 0.00